Abivax Stock-Based Compensation Growth & History (ABVX)
Abivax's stock-based compensation was €35.4M for fiscal 2025.
View full Abivax company overviewAbivax annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €35.4M | €15.2M | +75.02% |
| 2024 | 2024-12-31 | €20.2M | €12.0M | +147.27% |
| 2023 | 2023-12-31 | €8.2M | €7.0M | +602.66% |
| 2022 | 2022-12-31 | €1.2M | €336,000 | +40.58% |
| 2021 | 2021-12-31 | €828,000 | — | — |
Abivax quarterly stock-based compensation
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | €22.6M | €17.9M | +382.19% |
| Q4 2025 | 2025-12-31 | €12.9M | €8.4M | +189.43% |
| Q3 2025 | 2025-09-30 | €11.5M | €7.1M | +164.06% |
| Q2 2025 | 2025-06-30 | €6.3M | €666,000 | +11.75% |
| Q1 2025 | 2025-03-31 | €4.7M | −€1.1M | −18.52% |
| Q4 2024 | 2024-12-31 | €4.5M | — | — |
| Q3 2024 | 2024-09-30 | €4.3M | — | — |
| Q2 2024 | 2024-06-30 | €5.7M | — | — |
| Q1 2024 | 2024-03-31 | €5.8M | — | — |
Abivax stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, Abivax's stock-based compensation increased from €828,000 to €35.4M, a change of €34.6M. The latest reported quarter, Q1 2026, shows €22.6M.
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Abivax source filings ↗